Acrobiosystems Co

Acrobiosystems Co ROA

The Return on Assets (ROA) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 5.50 %. In the previous year, Return on Assets (ROA) was 4.25 % — a change of 29.48% (higher).

ROA

5.50 %

YoY

29.48%

Last updated:

In 2025, Acrobiosystems Co's return on assets (ROA) was 5.50 %, a 29.48% increase from the 4.25 % ROA in the previous year.

The Acrobiosystems Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
13.59 CNY
Jan 1, 2019
9.79 CNY
Jan 1, 2020
48.02 CNY
Jan 1, 2021
6.85 CNY
Jan 1, 2022
7.45 CNY
Jan 1, 2023
5.46 CNY
Jan 1, 2024
4.25 CNY
Jan 1, 2025
5.50 CNY
The Acrobiosystems Co ROA history
YEARROAYoY
5.50 %+29.48%
4.25 %-22.17%
5.46 %-26.69%
7.45 %+8.77%
6.85 %-85.74%
48.02 %+390.71%
9.79 %-27.98%
13.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding Acrobiosystems Co's Return on Assets (ROA)

Acrobiosystems Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Acrobiosystems Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Acrobiosystems Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Acrobiosystems Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Acrobiosystems Co stock

Return on Assets (ROA) of Acrobiosystems Co is 5.50 % in 2025.

Return on Assets (ROA) of Acrobiosystems Co changed from 4.25 % to 5.50 %, representing a 29.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Acrobiosystems Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Acrobiosystems Co